Skip to Main Content
An official website of the United States government
Login Change: CDAS is now using the NIH Researcher Auth Service (RAS) to manage our existing login options. When logging into CDAS, you will be taken to RAS, where you can select your preferred login provider to access CDAS.

Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors

Chang VC, Khan AA, Huang WY, Katki HA, Purdue MP, Landgren O, Hofmann JN

Affiliations

  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. chidan.chang@nih.gov.
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.

Abstract

N/A
Back to Publication Search

Publication Details

PubMed ID
35365600

Digital Object Identifier
10.1038/s41408-022-00642-4

Publication
Blood Cancer J. 2022 Apr 1; Volume 12 (Issue 4): Pages 51

Related CDAS Studies Related CDAS Studies